ate PET/CT acquisition for improved tissue characterization and assessment of treatment response: prospective data collection in clinically indicated examinations in oncology.
- Conditions
- C85C81C61C80C15C31C32C33C34C21
- Registration Number
- DRKS00027307
- Lead Sponsor
- niversitätsklinikum Tübingen
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 600
Justifying clinical indication for PET/CT examination,
- Patients with predominantly one of the following oncological diseases: Lymphoma (Hodgkin's, non-Hodgkin's), prostate cancer, neuroendocrine tumors, patients treated with radiation oncology (esophageal cancer, head and neck tumors, lung cancer, rectal cancer, anal cancer), cholangiocellular carcinoma, malignant melanoma, CUP,
- Patients able to grasp the nature and extent of pseudonymized prospective data collection,
- Patients who can tolerate a waiting time of 2-11 hours between regular and late PET/CT measurements with a maximum examination time of 30-60 minutes in the PET/CT scanner,
- Age =18 years,
- Written informed consent from the patient.
- Pregnant and breastfeeding women,
- Patients with claustrophobia,
- Patients with severely reduced general condition and/or problems/pain when lying on their backs, so that waiting time and further lying time may not be tolerated,
- Exclusion criteria according to Radiation Protection Ordinance,
- Limited capacity of the patient to give consent.
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Definition of an optimal time of examination for complementary late PET/CT in different oncological diseases.
- Secondary Outcome Measures
Name Time Method - Differentiation between tissues with nonspecific and/or inflammation-related radiotracer uptake and tissues with tumor-associated radiotracer uptake, <br>- Investigation of physiological late radiotracer enrichment of parenchymal reference organs (liver, spleen) versus radiotracer enrichment of parenchymal tumors with the aim of improving the lesion-to-background ratio,<br>- More specific assessment of treatment response of chemotherapies, immunotherapies and -modulators, radionuclide therapies, and radiotherapies,<br>- Investigation of progression-free survival and evaluation of (semi)-quantitative PET parameters with prognostic value,<br>- Investigation of dosimetric aspects of late PET acquisition.